Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25,734 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7,371
Recruiting: 3,969
Ph III recruiting: 536
Growth YoY: +9.5%
Industry share: 25%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3,407)

clinicaltrialsPublishedShowing 3,201–3,250 of 3,857 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06521866	Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer	recruiting	Phase 2	208	Fudan UniversityOTHER	1	Mar 14, 2025	clinicaltrials
NCT06869473	Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.(AVEC-119)	recruiting	Phase 2	67	Gruppo Oncologico del Nord-Ovest